Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Apr. 2026,
Medtronic receivedR$1,007 Mil more from issuing new shares than it paid to buy back shares.
It spentR$826 Mil paying down its debt.
It paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentR$4,571 Mil paying cash dividends to shareholders.
It spentR$81 Mil on other financial activities.
In all, MedtronicspentR$4,470 Mil on financial activities for the
three
months ended in Apr. 2026.
Medtronic (BSP:MDTC34) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Medtronic's issuance of stock for the
three
months ended in Apr. 2026 was R$3,197 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Medtronic's repurchase of stock for the
three
months ended in Apr. 2026 was R$-2,190 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Medtronic's net issuance of debt for the
three
months ended in Apr. 2026 was R$-826 Mil.
Medtronic spentR$826 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Medtronic's net issuance of preferred for the
three
months ended in Apr. 2026 was R$0 Mil.
Medtronic paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Medtronic's cash flow for dividends for the
three
months ended in Apr. 2026 was R$-4,571 Mil.
Medtronic spentR$4,571 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Medtronic's other financing for the
three
months ended in Apr. 2026 was R$-81 Mil.
Medtronic spentR$81 Mil on other financial activities.
Medtronic Cash Flow from Financing Related Terms
Medtronic Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Medtronic's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Medtronic's Cash from Financing for the fiscal year that ended in Apr. 2026 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-25,365 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of R$-25,365 Mil mean?
Medtronic (BSP:MDTC34) has a Cash Flow from Financing of R$-25,365 Mil as of Apr. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Medtronic and its competitors.
Is Medtronic's Cash Flow from Financing too high?
Medtronic's current Cash Flow from Financing is R$-25,365 Mil. Overall, Medtronic has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Cash Flow from Financing compare to SYK and BSX?
Medtronic's Cash Flow from Financing of R$-25,365 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Medtronic and its competitors. Medtronic's current Cash Flow from Financing is R$-25,365 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$63.88, compared to a current price of R$54.50 — trading 14.7% below its estimated fair value. The current Cash Flow from Financing is R$-25,365 Mil. Medtronic's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Cash Flow from Financing is R$-25,365 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$54.50 is trading 14.7% below its estimated GF Value™ of R$63.88.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for BSP:MDTC34:
Cash Flow from Financing: R$-25,365 Mil
GF Value™: R$63.88 vs. price of R$54.50 (14.7% below fair value)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
69GF Score
Get the complete analysis for BSP:MDTC34
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
